DOI: https://doi.org/10.22263/2312-4156.2023.5.52
V.A. Chyzhyk1, V.V. Ponomarev1, H.I. Ivanchik1, D.B. Nizheharodava1,2, M.M. Zafranskaya1,2
The dynamics of IL-10 in blood serum during the long-term period of cell therapy for Parkinson’s disease
1Institute for Advanced Training and Retraining of Healthcare Personnel of the Educational Establishment “Belarusian State Medical University”, Minsk, Republic of Belarus
2International Sakharov Environmental Institute of Belarusian State University, Minsk, Republic of Belarus
Vestnik VGMU. 2023;22(5):52-60.
Abstract.
Parkinson’s disease (PD) is a chronic, steadily progressive disease. Neuroinflammation and hyperactivation of the immune cells, along with the neurodegenerative process, play an important role in the occurrence and progression of PD. Interleukin 10 (IL-10) contributes to the development of the humoral component of the immune response and is considered as one of the laboratory indicators used to assess the level of neuroinflammation.
Objectives. To evaluate the dynamics of blood serum IL-10 concentration in patients with PD after cell therapy with autologous multipotent mesenchymal stromal cells (MMSCs).
Material and methods. The study included 36 patients with PD. The main group included 23 patients, the comparison group consisted of 13 patients with PD. Cell therapy with autologous MMSCs in the main group was carried out by two methods: either systemic (intravenous) or tandem (intravenous + intranasal) one. Patients from the comparison group received 0.9% saline (placebo) solution by the tandem method. Monitoring of the clinical and neurological status with an assessment of motor symptoms and taking blood samples from the cubital vein to determine the level of IL-10 were carried out before the first injection and 1, 3, 6, 9 and 12 months after the administration of MMSCs or placebo.
Results. A correlation between the reduction in the severity of motor symptoms and the level of anti-inflammatory IL-10 in the blood serum of patients with PD after MMSC therapy in the main group was found. In the second group a statistically significant decrease of IL-10 concentration was obtained in 12 months after placebo administration compared to 0-day.
Conclusions. The results obtained indicate the presence of a relationship between the dynamics of motor symptoms and fluctuations in the level of IL-10 in the blood serum. An increase in the concentration of IL-10 in the blood serum of a patient with PD after MMSC therapy can be considered as a biomarker of its effectiveness.
Keywords: Parkinson’s disease, mesenchymal multipotent stromal cells, neuroinflammation, motor symptoms, interleukin 10.
The research was conducted within the frames of task 19.17 “To elaborate and employ the method of Parkinson’s disease treatment with the use of cellular technologies” of the subprogram “Cells, organs and tissues transplantation” of the State Research Program (GPNI) “New methods of rendering medical aid” (State Registration No. 20171292).
References
1. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. Neuroinflammation and α- synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect. 2011 Jun;119(6):807-14. doi: http://dx.doi.org/10.1289/ehp.1003013
2. Yacoubian TA, Dean Fang YH, Gerstenecker A, Amara A, Stover N, Ruffrage L, et al. Brain and Systemic Inflammation in De Novo Parkinson's Disease. Mov Disord. 2023 May;38(5):743-54. doi: http://dx.doi.org/10.1002/mds.29363
3. Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol. 2012 Oct;237(2):318-34. doi: http://dx.doi.org/10.1016/j.expneurol.2012.06.025
4. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med. 2012 Jan;2(1):a009381. doi: http://dx.doi.org/10.1101/cshperspect.a009381
5. Thome AD, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff JR, et al. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease. NPJ Parkinsons Dis. 2021 May;7(1):41. doi: http://dx.doi.org/10.1038/s41531-021-00188-5
6. Land WG. The Role of Damage-Associated Molecular Patterns (DAMPs) in Human diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ Med J. 2015 May;15(2):e157-70
7. Molina-Holgado F, Grencis R, Rothwell NJ. Actions of exogenous and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia. 2001 Feb;33(2):97-106.
8. Liu TW, Chen CM, Chang KH. Biomarker of Neuroinflammation in Parkinson's Disease. Int J Mol Sci. 2022 Apr;23(8):4148. doi: http://dx.doi.org/10.3390/ijms23084148
9. Ramanzini LG, Camargo LFM, Silveira JOF, Bochi GV. Inflammatory markers and depression in Parkinson’s disease: a systematic review. Neurol Sci. 2022 Dec;43(12):6707-17. doi: http://dx.doi.org/10.1007/s10072-022-06363-7
10. Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, et al. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov Disord. 2016 Jul;31(7):995-1003. doi: http://dx.doi.org/10.1002/mds.26563
11. Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: A systematic review and meta-analysis. JAMA Neurol. 2016 Nov;73(11):1316-24. doi: http://dx.doi.org/10.1001/jamaneurol.2016.2742
12. Boika A, Aleinikava N, Chyzhyk V, Zafranskaya M, Nizheharodava D, Ponomarev V. Mesenchymal stem cells in Parkinson's disease: Motor and nonmotor symptoms in the early posttransplant period. Surg Neurol Int. 2020 Nov:11:380. doi: http://dx.doi.org/10.25259/SNI_233_2020
13. Chizhik VA, Boyko AV, Aleynikova NE, Ponomarev VV. Effect of cell therapy on the dynamics of motor symptoms of Parkinson's disease in long-term follow-up period. Med Novosti. 2022;(4):16-9. (In Russ.)
14. Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016 Jan;7(1):e2062. doi: http://dx.doi.org/10.1038/cddis.2015.327
15. Vu TC, Nutt JG, Holford NHG. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: http://dx.doi.org/10.1111/j.1365-2125.2012.04192.x
16. Yagi H, Soto-Gutierrez A, Kitagawa Y, Tilles AW, Tompkins RG, Yarmush ML. Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant. 2010;19(6):823-30. doi: http://dx.doi.org/10.3727/096368910X508942
17. Németh K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009 Jan;15(1):42-9. doi: http://dx.doi.org/10.1038/nm.1905
18. Deng Y, Zhang Y, Ye L, Zhang T, Cheng J, Chen G, et al. Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10- producing phenotype by secreting IL6 and HGF. Sci Rep. 2016 Dec:6:37566. doi: http://dx.doi.org/10.1038/srep37566
19. Luz-Crawford P, Djouad F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, et al. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. 2016 Feb;34(2):483-92. doi: http://dx.doi.org/10.1002/stem.2254
20. Schmidt A, Zhang XM, Joshi RN, Iqbal S, Wahlund C, Gabrielsson S, et al. Human macrophages induce CD4(+)Foxp3(+) regulatory T cells via binding and re-release of TGF-β. Immunol Cell Biol. 2016 Sep;94(8):747-62. doi: http://dx.doi.org/10.1038/icb.2016.34
21. Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol. 2019 Jun:10:1191. doi: http://dx.doi.org/10.3389/fimmu.2019.01191
22. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW et al. Human mesenchymal stem cells reduce mortality and bacteremia in gramnegative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012 May;302(10):L1003-13. doi: http://dx.doi.org/10.1152/ajplung.00180.2011
23. de Witte SFH, Luk F, Parraga JMS, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of msc by monocytic cells. Stem Cells. 2018 Apr;36(4):602-615. doi: http://dx.doi.org/10.1002/stem.2779
Information about authors:
V.A. Chyzhyk – lecturer of the Chair of Neurology & Neurosurgery, Institute for Advanced Training and Retraining of Healthcare Personnel of the Educational Establishment “Belarusian State Medical University”,
e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Veronika A. Chyzhyk;
V.V. Ponomarev – Doctor of Medical Sciences, professor, head of the Chair of Neurology & Neurosurgery, Institute for Advanced Training and Retraining of Healthcare Personnel of the Educational Establishment “Belarusian State Medical University”;
H.I. Ivanchik – senior research officer of the Department for Immunology & Biomedical Technologies of the Research Laboratory, Institute for Advanced Training and Retraining of Healthcare Personnel of the Educational Establishment “Belarusian State Medical University”;
D.B. Nizheharodava – Candidate of Biological Sciences, associate professor, leading scientific officer of the Department for Immunology & Biomedical Technologies of the Research Laboratory, Institute for Advanced Training and Retraining of Healthcare Personnel of the Educational Establishment “Belarusian State Medical University”, associate professor of the Chair of Immunology, International Sakharov Environmental Institute of Belarusian State University;
M.M. Zafranskaya – Doctor of Medical Sciences, professor, principal scientific officer of the Department for Immunology & Biomedical Technologies of the Research Laboratory, Institute for Advanced Training and Retraining of Healthcare Personnel of the Educational Establishment “Belarusian State Medical University”, head of the Chair of Immunology, International Sakharov Environmental Institute of Belarusian State University.
